Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Blood (2023) 142 (Supplement 1): 62.

https://doi.org/10.1182/blood-2023-183029

Published: 2023

Journal Articles

Targeting HUWE1 in Multiple Myeloma Leads to Impaired Replicative Stress Response and Enhanced Sensitivity to Bortezomib

Jonathan J Morgan, Bryony G Kennedy, Rich Williams, Ken I Mills, Lisa J Crawford

Blood (2023) 142 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2023-185913

Published: 2023

Journal Articles

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

Blood (2022) 140 (Supplement 1): 551–554.

https://doi.org/10.1182/blood-2022-167480

Published: 2022

Journal Articles

CHD4 Loss Alters Chromatin Accessibility Giving Rise to Sensitivity to DNA Damage Repair Compounds in Acute Myeloid Leukaemia

Deirdra Venney, Graeme M Greenfield, Lauren V Cairns, Paul Strain, Áine E McGill, Jonathan J Morgan, Róisín M McAvera, Fatemeh Mirzadeh, Yaser Atlasi, Adone Mohd-Sarip, Ken I Mills

Blood (2022) 140 (Supplement 1): 8702–8703.

https://doi.org/10.1182/blood-2022-162764

Published: 2022

Journal Articles

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Blood (2022) 140 (Supplement 1): 6053–6055.

https://doi.org/10.1182/blood-2022-165088

Published: 2022

Journal Articles

New Mechanistic and Therapeutic Insights into Purified Phospholipase A 2 from Pseudechis Australis Snake Venom - a Novel Anticancer Agent for the Treatment of Precursor B-Cell Acute Lymphoblastic Leukaemia

James Boncan, Jeremy Hamilton, Karen McCloskey, Ken I Mills

Blood (2022) 140 (Supplement 1): 3120–3121.

https://doi.org/10.1182/blood-2022-166114

Published: 2022

Journal Articles

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

Blood (2022) 140 (Supplement 1): 13122–13124.

https://doi.org/10.1182/blood-2022-163285

Published: 2022

Journal Articles

Application of Hallmarks of Cancer Gene Signatures Reveals Novel Energetics-Associated Subtypes with Distinct Survival Outcomes in AML

Paul Strain, Enya Scanlon, Gera Jellema, Richard Kennedy, Ken I Mills, Jaine Blayney

Blood (2022) 140 (Supplement 1): 11815–11816.

https://doi.org/10.1182/blood-2022-160171

Published: 2022

Journal Articles

Multiplex Drug Screening Identifies a Novel Therapeutic Backbone for the Treatment of Acute Myeloid Leukaemia

Lauren V Cairns, Kathryn Clarke, Mark Catherwood, Ken I Mills

Blood (2022) 140 (Supplement 1): 7814–7815.

https://doi.org/10.1182/blood-2022-163107

Published: 2022

Journal Articles

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

Blood (2022) 140 (Supplement 1): 739–742.

https://doi.org/10.1182/blood-2022-167138

Published: 2022

Journal Articles

UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model

Graeme M Greenfield, Deirdra Venney, Jaine Blayney, Mary Frances McMullin, Ken I Mills

Blood (2022) 140 (Supplement 1): 6752–6754.

https://doi.org/10.1182/blood-2022-167709

Published: 2022

Journal Articles

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Tommaso Matteuzzi, Daniele Dall'Olio, Eric Sträng, Alessandra Merlotti, Javier Martinez Elicegui, Axel Benner, Maral Saadati, Julia Krzykalla, Caroline A. Heckman, Ana Heredia Casanoves, Jurjen Versluis, María Abáigar, Alberto Hernandez-Sanchez, Laura Jamilis, Peter JM Valk, Klaus H. Metzeler, Rosa Ayala, Joaquin Martinez Lopez, Herve Dombret, Pau Montesinos, Jorge Sierra, Claude Preudomme, Frederick Damm, Ken I Mills, Raúl Azibeiro Melchor, Jiří Mayer, Christian Thiede, Maria Teresa Voso, Sergio Amadori, Guillermo Sanz, Frederico Calado, Konstanze Döhner, Verena I Gaidzik, Michael Heuser, Torsten Haferlach, Marta Sobas, Amin T. Turki, Dirk Reinhardt, Rubén Villoria Medina, Michel van Speybroeck, Renate Schulze-Rath, Jesús M Hernández Rivas, Brian J.P Huntly, Hartmut Döhner, Gert J. Ossenkoppele, Castellani Gastone, Lars Bullinger

Blood (2021) 138 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2021-152215

Published: 2021

Journal Articles

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Manja Meggendorfer, Ferran Nadeu, Christian Brieghel, Helen Parker, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E Rodríguez-Vicente, Rocio Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquin Martinez-Lopez, Javier de la Serna, Jesús M Hernández Rivas, Patrick Thornton, Maria Jose Larrayoz, María José Calasanz, Zoltán Mátrai, Csaba Bodor, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, María José Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken I Mills, Gianluca Gaidano, Carsten Utoft Niemann, Elías Campo, Jonathan C Strefford, Paolo Ghia, Kostas Stamatopoulos, Richard Rosenquist

Blood (2021) 138 (Supplement 1): 2617.

https://doi.org/10.1182/blood-2021-150648

Published: 2021

Journal Articles

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 4041.

https://doi.org/10.1182/blood-2021-149521

Published: 2021

Journal Articles

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

Blood (2021) 138 (Supplement 1): 608.

https://doi.org/10.1182/blood-2021-150766

Published: 2021

Journal Articles

TRIM33 Loss in Multiple Myeloma Impairs the DNA Damage Response Resulting in Sensitivity to PARP and ATR Inhibitors

Roisin M McAvera, Jonathan J Morgan, Ken I Mills, Lisa J Crawford

Blood (2021) 138 (Supplement 1): 1570.

https://doi.org/10.1182/blood-2021-147728

Published: 2021

Journal Articles

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Harmony Estelle Black, BSc, Satpal Jhujh, Grant S Stewart, BSc, PhD, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2019) 134 (Supplement_1): 1255.

https://doi.org/10.1182/blood-2019-129828

Published: 2019

Journal Articles

Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma

Lisa J Crawford, BSc, PhD, David Campbell, BSc, PhD, Ken I Mills, PhD FRCPath, BSc, Alexandra E Irvine, PhD FRCPath

Blood (2018) 132 (Supplement 1): 4512.

https://doi.org/10.1182/blood-2018-99-118294

Published: 2018

Journal Articles

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

Katrina Lappin, PhD BSc, Kyle B Matchett, PhD, Jaine Blayney, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2018) 132 (Supplement 1): 2731.

https://doi.org/10.1182/blood-2018-99-111234

Published: 2018

Journal Articles

The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients

Clare Crean, BA, MSc, Kienan I Savage, PhD, Ken I Mills, PhD FRCPath, BSc

Blood (2018) 132 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2018-99-115854

Published: 2018

NARROW

Machine Learning Provides Individualized Prediction of Outcomes after First Complete Remission in Adult AML Patients - Results from the Harmony Platform

Targeting HUWE1 in Multiple Myeloma Leads to Impaired Replicative Stress Response and Enhanced Sensitivity to Bortezomib

Rearrangements Involving 11q23/ KMT2A : Mutational Landscape and Prognostic Implications - Results of the Harmony Alliance AML Database

CHD4 Loss Alters Chromatin Accessibility Giving Rise to Sensitivity to DNA Damage Repair Compounds in Acute Myeloid Leukaemia

Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

New Mechanistic and Therapeutic Insights into Purified Phospholipase A 2 from Pseudechis Australis Snake Venom - a Novel Anticancer Agent for the Treatment of Precursor B-Cell Acute Lymphoblastic Leukaemia

Enabling the Implementation of Next-Generation Sequencing into Clinical Diagnosis: Nemhesys Project

Application of Hallmarks of Cancer Gene Signatures Reveals Novel Energetics-Associated Subtypes with Distinct Survival Outcomes in AML

Multiplex Drug Screening Identifies a Novel Therapeutic Backbone for the Treatment of Acute Myeloid Leukaemia

Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML - Results of the European Harmony Alliance

UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model

Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study

Different Prognostic Impact of Recurrent Gene Mutations in IGHV-Mutated and IGHV-Unmutated Chronic Lymphocytic Leukemia: A Retrospective, Multi-Center Cohort Study By Eric, the European Research Initiative on CLL, in Harmony

Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation

Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database

TRIM33 Loss in Multiple Myeloma Impairs the DNA Damage Response Resulting in Sensitivity to PARP and ATR Inhibitors

STAG2 Loss Gives Rise to Therapeutically Targetable DNA Damage Repair Defects and Altered Replication Fork Dynamics in Acute Myeloid Leukaemia

Relationship between HUWE1 Mutation and Functionality in Multiple Myeloma

Identifying Combination Therapies Targeting Apoptosis Pathways in Pediatric Acute Myeloid Leukemia (CAuSAL Study)

The Potential of Using DNA Damage Repair Deficiency As a Biomarker for Cytarabine Response in AML Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only